drugset / Trial / NCT02576327

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

NCT02576327

Phase 4 Unknown 130 enrolled Jun Zhu
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Timeline

Start
2015-10
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg
Background Dexamethasone Small molecule 10 mg
Background Tropisetron Small molecule 5 mg

Indications

No indication recorded.